CU06-1004 as a promising strategy to improve anti-cancer drug efficacy by preventing vascular leaky syndrome

Background: Interleukin-2 (IL-2) is the first cancer therapeutic agent with an immunomodulatory function. Although it has been experimentally proven to be effective against metastatic renal cell carcinoma and metastatic melanoma, the clinical application of high-dose IL-2 (HDIL-2) has been limited b...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Songyi, Lee, Sunghye, Kim, Dongyeop, Kim, Hyejeong, Kwon, Young-Guen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499177/
https://www.ncbi.nlm.nih.gov/pubmed/37711172
http://dx.doi.org/10.3389/fphar.2023.1242970

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499177/
https://www.ncbi.nlm.nih.gov/pubmed/37711172
http://dx.doi.org/10.3389/fphar.2023.1242970

Ejemplares similares